Femasys Replaces Two Board Members

Femasys Inc. has appointed Keith J. Kendall and Alistair Milnes to its Board of Directors.

The pair replace John Dyett, the co-CEO of Salem Partners LLC and Salem Partners Wealth Management LLC, and John Adams, former CEO and president of Adams Respiratory Therapeutics. Dyett and Adams have both been board members for more than eight years. 

“We are excited to welcome Keith Kendall and Alistair Milnes to our board. Both serve as a great fit with our existing board due to their very expansive experience as life sciences executives, which will be invaluable as we continue to expand our commercial portfolio of biomedical solutions available to women worldwide,” Femasys Founder, President, and CEO Kathy Lee-Sepsick said. “Kendall brings decades of leadership and financial and operating experience. Milnes’ experience as a biotechnology executive includes leadership experience in expediting company growth and market expansion. We are immensely thankful to John Dyett and John Adams for their long-standing service with thecCompany, with John Dyett being instrumental in his support and guidance for our IPO and financings and John Adams offering operating insight from our time as a private company to becoming a public company.”
 
Kendall, who replaces Dyett as Audit Committee chair, is founder and CEO at KSquared Strategic Advisors, a firm that provides strategic, corporate development and capital markets advisory services. Previously, he was CEO and president of Aquestive Therapeutics, a commercial-stage, biopharmaceutical drug delivery company; before that, he was its chief operating officer (COO) and chief financial officer. Kendall has served in various business leadership positions for blue-chip companies such as Hewlett Packard Financial Services, including working as vice president and managing director of the Americas, and he held various positions with AT&T Capital Corporation, including president of AT&T Credit Corporation and NCR Credit Corporation.
 
Kendall earned his bachelor of science degree from St. John’s University and an MBA from Pace University.

“I look forward to working together with Femasys’ management in support of the mission to change women’s health at this crucial time of the company’s development, as well as leading the audit committee, following multiple product approvals and with key potential approvals on the horizon,” Kendall said.
 
Milnes is COO at Bicycle Therapeutics, a clinical-stage biopharmaceutical company, and also served as vice president, Human Resources and Communications there. Previously, he provided independent human resources consulting services, and also was a strategic advisor at Rio Tinto with a focus on transformation, people, and communications, and in roles of increasing responsibility at Gazprom Marketing & Trading Ltd., including serving as director of Global Human Resources and Communications.
 
Milnes earned his bachelor of arts degree from Edinburgh Napier University.
 
“I am thrilled to join Femasys’ board of directors at this exciting time of growth for the company,” Milnes stated. “I look forward to applying my expertise to the company’s next phase of growth as it becomes more established in its commercial stage of development.”
 
Femasys Inc. is a biomedical company developing products and product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc permanent birth control and FemaSeed localized directional insemination for infertility. The company’s products currently marketed in the United States include FemVue for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath, an intrauterine catheter for selective evaluation of the fallopian tubes, and FemCerv, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling.